Rosen Law Firm has initiated a class action lawsuit against Ultragenyx Pharmaceutical Inc., targeting investors who acquired the company's common stock during the period spanning August 3, 2023 through December 26, 2025. The litigation alleges that company leadership made materially false and misleading statements regarding the clinical efficacy of setrusumab, the firm's investigational therapeutic candidate.
Central to the complaint is a discrepancy between the company's public assertions and the drug's actual clinical profile. While setrusumab demonstrated the ability to increase bone mineral density in patient populations, the lawsuit contends that management misrepresented this biochemical outcome as translating to clinically meaningful reductions in fracture incidence. This distinction between surrogate endpoints and clinical outcomes represents a critical point of contention in the securities claim.
Investors considering participation in the action must act expeditiously, as the deadline to submit applications to serve as lead plaintiff is April 6, 2026. Class members are advised to retain legal counsel experienced in securities litigation to evaluate their eligibility and potential recovery options under applicable securities laws.